628 related articles for article (PubMed ID: 18624866)
21. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
[TBL] [Abstract][Full Text] [Related]
22. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
[TBL] [Abstract][Full Text] [Related]
23. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
Spergel JM; Boguniewicz M; Paller AS; Hebert AA; Gallagher PR; McCormick C; Parneix-Spake A; Hultsch T
Br J Dermatol; 2007 Aug; 157(2):378-81. PubMed ID: 17573885
[TBL] [Abstract][Full Text] [Related]
24. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Frankel A; Sohn A; Patel RV; Lebwohl M
J Drugs Dermatol; 2011 Jun; 10(6):666-72. PubMed ID: 21637908
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies.
Paller AS; Lebwohl M; Fleischer AB; Antaya R; Langley RG; Kirsner RS; Blum RR; Rico MJ; Jaracz E; Crowe A; Linowski GJ;
J Am Acad Dermatol; 2005 May; 52(5):810-22. PubMed ID: 15858471
[TBL] [Abstract][Full Text] [Related]
26. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients.
Oppel T; Pavicic T; Kamann S; Bräutigam M; Wollenberg A
J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1175-80. PubMed ID: 17894701
[TBL] [Abstract][Full Text] [Related]
27. StabiEL: stabilization of skin condition with Elidel--a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.
Gollnick H; Luger T; Freytag S; Bräutigam M;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1319-25. PubMed ID: 18540990
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT.
Bauer A; Lange N; Matterne U; Meurer M; Braeutigam M; Diepgen TL
J Dtsch Dermatol Ges; 2012 Jun; 10(6):426-33. PubMed ID: 22112014
[TBL] [Abstract][Full Text] [Related]
29. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
Abramovits W; Fleischer AB; Jaracz E; Breneman D
J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis.
Luger TA; Gollnick H; Schwennesen T; Bextermöller R; Freytag S; Bräutigam M
J Dtsch Dermatol Ges; 2007 Oct; 5(10):908-14. PubMed ID: 17910673
[TBL] [Abstract][Full Text] [Related]
31. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%.
Fowler J; Johnson A; Chen M; Abrams K
Cutis; 2007 Jan; 79(1):65-72. PubMed ID: 17330625
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
Kirsner RS; Heffernan MP; Antaya R
Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.
Fleischer AB; Abramovits W; Breneman D; Jaracz E;
J Dermatolog Treat; 2007; 18(3):151-7. PubMed ID: 17538803
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
36. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
38. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
Kapoor R; Hoffstad O; Bilker W; Margolis DJ
Pediatr Dermatol; 2009; 26(6):682-7. PubMed ID: 20199441
[TBL] [Abstract][Full Text] [Related]
39. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
Dawid M; Veensalu M; Grassberger M; Wolff K
J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
